ALAndreas Lingel

Andreas Lingel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andreas Lingel has a total of 295 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Scope Concept: Defined Chemical Space for Identifying Ligand-Efficient, Tractable Hits Applied to Drug Discovery Targets Trypanosomal CLK1, 14–3–3/Estrogen Receptor-α, and SARS-CoV-2 Mpro

    by Johanna M. Jansen, Wilian Cortopassi, Daniel Fuller, Peter Ertl, Eric Fang, Rishi Raj Gupta, Weiping Jia, Jan Jiricek, Mark Knapp, Andreas Lingel, et al.

    Scope is a hit-finding concept that explores a chemical space in between fragments and fully elaborated molecules from traditional low molecular weight (LMW) libraries. It emphasizes high medicinal chemistry tractability through a focus on compound quality, ligand efficiency, and selected physical-chemical property ranges. The Scope chemical space definition seeks to strike a balance between the ability to cover chemical space with a 10k–50k compound set for medium-throughput screening and obtaining hits with sufficient functionality to yield low- to mid-micromolar potency. Scope chemical space is distinct from other rule-based chemical spaces, and we introduce the concept of Scope ring systems (ring-X-ring) as both a foundation for intentional functionalization targeting sufficient potency and as an organizing principle for characterizing and enhancing compound libraries. A Scope screening set has been designed from the Scope chemical space for hit finding with SPR, native mass spectrometry, DSF, and biochemical methods. This Scope set maintains comparable primary hit rates to general diversity sets even when screening at higher concentrations, which allows for efficient hit validation. The Scope set outperforms diversity sets when considering ligand efficiency and hit rates after counter-screening, which makes it a preferred set. Case studies include the trypanosomal CLK1 kinase target, a molecular glue project with 14–3–3 and estrogen receptor-α, and the SARS-CoV-2 main protease. These studies exemplify how the 10k Scope set delivers diverse and ligand-efficient hits with tractable potency across diverse binding sites and support the idea that a carefully designed 10k Scope set can provide meaningful diversity for screening in a broad drug discovery portfolio. The Scope principles have demonstrated value in hit-finding campaigns and have changed practices for compound acquisition, hit-list triaging, and screening.

  • A small-molecule VHL molecular glue degrader for cysteine dioxygenase 1

    by Antonin Tutter, Dennis Buckley, Andrei A. Golosov, Xiaolei Ma, Wei Shu, Daniel J. J. McKay, Veronique Darsigny, Dustin Dovala, Rohan Beckwith, Jonathan Solomon, et al.

    The von Hippel–Lindau tumor suppressor gene product (pVHL) is an E3 ligase substrate receptor that binds proline-hydroxylated hypoxia-inducible factor HIF1α, leading to its ubiquitin-dependent degradation. By using protein arrays, we identified a small molecule that binds the HIF1α-binding pocket on pVHL and functions as a molecular glue degrader of the neosubstrate cysteine dioxygenase (CDO1) by recruiting it into the VHL–Cullin–RING E3 ligase complex and leading to its selective degradation. The CDO1-binding region involved in VHL recruitment was characterized through a combination of mutagenesis and protein–protein docking coupled with molecular-dynamics-based solvation analysis. The X-ray structure of the ternary complexes of VHL, CDO1 and degrader molecules confirms the binding region prediction and provides atomic insights into key molecular glue interactions.


  • Intrinsically Disordered Regions in the Transcription Factor MYC:MAX Modulate DNA Binding via Intramolecular Interactions

    by Stefan Schütz, Christian Bergsdorf, Sandra Hänni-Holzinger, Andreas Lingel, Martin Renatus, Alvar D. Gossert, Wolfgang Jahnke

    The basic helix-loop-helix leucine zipper (bHLH-LZ) transcription factor (TF) MYC is in large part an intrinsically disordered oncoprotein. In complex with its obligate heterodimerization partner MAX, MYC preferentially binds E-Box DNA sequences (CANNTG). At promoters containing these sequence motifs, MYC controls fundamental cellular processes such as cell cycle progression, metabolism, and apoptosis. A vast network of proteins in turn regulates MYC function via intermolecular interactions. In this work, we establish another layer of MYC regulation by intramolecular interactions. We used nuclear magnetic resonance (NMR) spectroscopy to identify and map multiple binding sites for the C-terminal MYC:MAX DNA-binding domain (DBD) on the intrinsically disordered regions (IDRs) in the MYC N-terminus. We find that these binding events in trans are driven by electrostatic attraction, that they have distinct affinities, and that they are competitive with DNA binding. Thereby, we observe the strongest effects for the N-terminal MYC box 0 (Mb0), a conserved motif involved in MYC transactivation and target gene induction. We prepared recombinant full-length MYC:MAX complex and demonstrate that the interactions identified in this work are also relevant in cis, i.e., as intramolecular interactions. These findings are supported by surface plasmon resonance (SPR) experiments, which revealed that intramolecular IDR:DBD interactions in MYC decelerate the association of MYC:MAX complexes to DNA. Our work offers new insights into how bHLH-LZ TFs are regulated by intramolecular interactions, which open up new possibilities for drug discovery.


  • Open Access

    Discovery of a selective and biologically active low-molecular weight antagonist of human interleukin-1β

    by Ulrich Hommel, Konstanze Hurth, Jean-Michel Rondeau, Anna Vulpetti, Daniela Ostermeier, Andreas Boettcher, Jacob Peter Brady, Michael Hediger, Sylvie Lehmann, Elke Koch, et al.

    Human interleukin-1β (hIL-1β) is a pro-inflammatory cytokine involved in many diseases. While hIL-1β directed antibodies have shown clinical benefit, an orally available low-molecular weight antagonist is still elusive, limiting the applications of hIL-1β-directed therapies. Here we describe the discovery of a low-molecular weight hIL-1β antagonist that blocks the interaction with the IL-1R1 receptor. Starting from a low affinity fragment-based screening hit 1, structure-based optimization resulted in a compound (S)-2 that binds and antagonizes hIL-1β with single-digit micromolar activity in biophysical, biochemical, and cellular assays. X-ray analysis reveals an allosteric mode of action that involves a hitherto unknown binding site in hIL-1β encompassing two loops involved in hIL-1R1/hIL-1β interactions. We show that residues of this binding site are part of a conformationally excited state of the mature cytokine. The compound antagonizes hIL-1β function in cells, including primary human fibroblasts, demonstrating the relevance of this discovery for future development of hIL-1β directed therapeutics.


  • Open Access

    Quantitative and functional characterisation of extracellular vesicles after passive loading with hydrophobic or cholesterol-tagged small molecules

    by Gwenola Tréton, Claudia Sayer, Melanie Schürz, Maria Jaritsch, Anna Müller, Cristian-Tudor Matea, Vesna Stanojlovic, Heloisa Melo-Benirschke, Celine Be, Caroline Krembel, et al.


  • JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors

    by Edwige Lorthiois, Marc Gerspacher, Kim S. Beyer, Andrea Vaupel, Catherine Leblanc, Rowan Stringer, Andreas Weiss, Rainer Wilcken, Daniel A. Guthy, Andreas Lingel, et al.

    Rapid emergence of tumor resistance via RAS pathway reactivation has been reported from clinical studies of covalent KRASG12C inhibitors. Thus, inhibitors with broad potential for combination treatment and distinct binding modes to overcome resistance mutations may prove beneficial. JDQ443 is an investigational covalent KRASG12C inhibitor derived from structure-based drug design followed by extensive optimization of two dissimilar prototypes. JDQ443 is a stable atropisomer containing a unique 5-methylpyrazole core and a spiro-azetidine linker designed to position the electrophilic acrylamide for optimal engagement with KRASG12C C12. A substituted indazole at pyrazole position 3 results in novel interactions with the binding pocket that do not involve residue H95. JDQ443 showed PK/PD activity in vivo and dose-dependent antitumor activity in mouse xenograft models. JDQ443 is now in clinical development, with encouraging early phase data reported from an ongoing Phase Ib/II clinical trial (NCT04699188).


  • The Disordered MAX N-terminus Modulates DNA Binding of the Transcription Factor MYC:MAX

    by Stefan Schütz, Christian Bergsdorf, Benedikt Goretzki, Andreas Lingel, Martin Renatus, Alvar D. Gossert, Wolfgang Jahnke


  • Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies

    by Ying Huang, Martin Sendzik, Jeff Zhang, Zhenting Gao, Yongfeng Sun, Long Wang, Justin Gu, Kehao Zhao, Zhengtian Yu, Lijun Zhang, et al.

    Polycomb Repressive Complex 2 (PRC2) plays an important role in transcriptional regulation during animal development and in cell differentiation, and alteration of PRC2 activity has been associated with cancer. On a molecular level, PRC2 catalyzes methylation of histone H3 lysine 27 (H3K27), resulting in mono-, di-, or trimethylated forms of H3K27, of which the trimethylated form H3K27me3 leads to transcriptional repression of polycomb target genes. Previously, we have shown that binding of the low-molecular-weight compound EED226 to the H3K27me3 binding pocket of the regulatory subunit EED can effectively inhibit PRC2 activity in cells and reduce tumor growth in mouse xenograft models. Here, we report the stepwise optimization of the tool compound EED226 toward the potent and selective EED inhibitor MAK683 (compound 22) and its subsequent preclinical characterization. Based on a balanced PK/PD profile, efficacy, and mitigated risk of forming reactive metabolites, MAK683 has been selected for clinical development.


  • Open Access

    Comprehensive and high-throughput exploration of chemical space using broadband 19F NMR-based screening

    by Andreas Frank, Christelle Henry, Burkhard Luy, Andrew Proudfoot, Andreas Lingel, Regis Denay, Alexandra Frommlet, Tony Reinsperger, Ulrich Hommel, Anna Vulpetti, et al.

  • Open Access

    Inside Cover: Comprehensive and High‐Throughput Exploration of Chemical Space Using Broadband 19F NMR‐Based Screening (Angew. Chem. Int. Ed. 35/2020)

    by Andreas Lingel, Anna Vulpetti, Tony Reinsperger, Andrew Proudfoot, Regis Denay, Alexandra Frommlet, Christelle Henry, Ulrich Hommel, Alvar D. Gossert, Burkhard Luy, et al.